Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces the publication of its 2021 Universal Registration Document, filed with the French Financial Market Authorities, Autorité des Marchés Financiers, on April 30, 2021.
April 30, 2021
· 3 min read